32 results about "Actin" patented technology

The present invention relates to an adeno-associated virus (AAV) vector comprising in the 5' to 3' direction: a first AAV2 ITR sequence; a CMV enhancer sequence; a chicken β-actin promoter sequence; a nucleic acid sequence encoding an apolipoprotein 2 (APOE2) polypeptide comprising a Christchurch mutation; a polyA sequence; and a second AAV2 ITR sequence.

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to application of dsRNA of a targeted actin coding gene. The invention provides application of dsRNA of a targeted actin coding gene in prevention and treatment of crop anthracnose, the nucleotide sequence of the dsRNA is shown as SEQ ID No.2, the dsRNA is obtained by transcription of a target gene segment of a colletotrichum CaACTIN gene, and the nucleotide sequence of the target gene segment of the colletotrichum CaACTIN gene is shown as SEQ ID No.1. The dsRNA is loaded by a nano-material layered double hydroxide, so that the dsRNA can be applied to prevention and treatment of crop anthracnose, and the target gene segment of the colletotrichum CaACTIN gene is obtained through transcription of the target gene segment of the colletotrichum CaACTIN gene and the target gene segment of the colletotrichum CaACTIN gene. The pathogenicity of mango colletotrichum gloeosporioides and banana colletotrichum gloeosporioides can be obviously reduced, and the application prospect of efficient and targeted control of crop anthracnose is achieved.

The invention belongs to the technical field of biological medicine, and discloses a protein nanomotor based on disulfide death and a preparation method and application thereof. The invention discloses a protein nanomotor, which comprises cystine or pharmaceutically acceptable salts thereof, and an enzyme connected with the cystine or the pharmaceutically acceptable salts thereof, the enzyme comprises glucose oxidase and an enzyme with a matrix degradation function, and the protein nano motor provided by the invention can trigger disulfide death of tumor (such as lung cancer) cells, so that a cell actin skeleton generates a large number of disulfide bonds and seriously shrinks, and finally, the cell structure comprehensively collapses and dies. Therefore, efficient killing of tumors is realized. Through synergistic effects of microenvironment remodeling, self-driven intra-tumor penetration promotion and disulfur death induction, the tumor treatment effect is significantly enhanced.

The present invention features promoters providing for DNA transcription. The promoters comprise: (1) a promoter core derived from the human peptidyl-prolyl isomerase G (PPIG) promoter, ATP citrate lyase (ACLY) promoter, actin gamma (ACTG1) promoter, actin related protein 2 (ACTR2) promoter, actin related protein 2 / 3 complex subunit 2 (ARPC2) promoter, or the vinculin (VCL) promoter; and / or (2) ocular specific transcription factor binding motifs from CRX, OTX2, and / or NRL.

The invention provides a reference gene combination for real-time fluorescent quantitative PCR (Polymerase Chain Reaction) of indocalamus as well as a primer pair combination and application of the reference gene combination, and belongs to the technical field of plant molecular biology. In combination with indocalamus transcriptome data analysis and cross validation of four algorithms, reference genes, MD10B, PP2A, eIF1A, Ite23725, eIF4A, 60S and UBP1, suitable for indocalamus are systematically screened out, optimal reference gene combinations under different experimental conditions (drought, salt, waterlogging stress and different tissues) are refined, and the method is scientific and rigorous and has good application prospects. And a precise tool is provided for gene expression analysis of the indocalamus in different research directions. The screened reference genes show extremely high expression stability in specific stress and tissues after being combined, and the expression stability is far better than that of traditional housekeeping genes such as Actin and UBI. The specific primer has high amplification efficiency, and ensures the accuracy of qRT-PCR results.

The application belongs to the technical field of cell biology, and provides an oocyte in vitro maturation culture medium additive and application thereof. The experimental results of the application show that coumarin 106 can improve the meiosis process blockage of oocytes, reduce the morphological proportion of abnormal spindle and the proportion of misaligned chromosomes, restore the level of acetylated tubulin, improve microtubule stability, improve the expression level of actin in the spindle of oocytes, improve the misdistribution and expression decrease of mitochondria in oocytes, improve the level of mitochondrial membrane potential, improve the fluorescence signal of cortical granules and specific cortical granule proteases in oocytes, improve the fertilization rate, reduce the level of reactive oxygen species and DNA damage in oocytes, and reduce the occurrence of early apoptosis in oocytes. The culture medium prepared by using coumarin 106 can be used for promoting oocyte in vitro maturation.

Provided herein are recombinant self-complementary adeno-associated virus (scAAV) nucleic acid vectors containing ubiquitous eukaryotic promoters, such as elongation factor 1 alpha (EF1α), chicken beta-actin (CBA), and hybrid chicken beta-actin (CBh), followed by a dominant-negative RhoA. Also provided herein are methods of using the vectors, including intraocular injection (e.g., intracameral injection) to reduce intraocular pressure (IOP). Also provided herein are plasmids, recombinant scAAV particles, compositions, formulations, and other methods of use related to such vectors.

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers thereof, which are useful for modulating or degrading proteins expressed by one or more SWI / SNF related matrix associated actin dependent chromatin regulatory factor A subfamily (SMARCA) (e.g., SMARCA2 and / or SMARCA4). I

Protein biosensors for drug discovery, such as a high-throughput assay utilizing TR-F to detect the properties of binding proteins (e.g., actin-binding proteins, ABPs) using a fluorescence lifetime plate reader and fluorescent probes. In particular, the present invention is a new use of TR-F technique to rapidly evaluate binding of F-actin (− or +Tm) with cMyBP-C in solution. Changes in labeled actin fluorescence lifetime due to cMyBP-C phosphorylation and / or HCM mutations correlated with binding measured by traditional cosedimentation. The present invention features methods for HTS for identifying molecules that modulate cMyBP-C or cMyBP-C-actin complex.

The invention provides a primer for specifically detecting genome DNA residues in sisal hemp cDNA and a method and application thereof. According to the invention, a beta-ACTIN gene is found in housekeeping genes stably expressed in each tissue of sisal hemp, and a unique sequence difference exists in the beta-ACTIN gene of the sisal hemp by comparing a DNA sequence and a cDNA sequence of the genome. On the basis, a pair of specific primers is developed, cDNA and gDNA of the sisal hemp can be clearly distinguished in common agarose gel electrophoresis on the basis of the length difference of amplified fragments, and gDNA pollution residues can be accurately detected in sisal hemp of different sources and varieties. The detection primer has the advantages of being high in specificity, good in stability, high in universality, simple in detection method, economical, practical and the like, and an efficient and specific standardized quality control tool is provided for evaluating sisal hemp RNA extraction quality and guaranteeing reliability of subsequent molecular experiment data.

The present invention relates to a biomarker for measuring anticancer drug resistance comprising a gene expressed in a group of cancer cells, wherein the gene releases an anticancer drug that has penetrated into the group of cancer cells to the outside of the group of cancer cells, wherein the gene comprises a gene selected from the group consisting of ABCG1, p-STAT3, STAT3, p-AKT, AKT, p-ERK, ERK, β-actin, ACTA2, GAS6, FAP, PDPN, COL1A1, AXL, and combinations thereof.

The invention belongs to the technical field of polysaccharides, and particularly discloses application of sulfated seaweed polysaccharides in preparation of anti-hepatic fibrosis drugs. According to a structural unit of the seaweed sulfated polysaccharide SPW-05-S2, 1, 4-beta-glucuronic acid and 1, 2-alpha-mannose are alternately connected to form a main chain, mannose, xylose, galactose and fucose form branch chains, the branch chains are located on the C-6 site and the C-3 site of the 1, 2-alpha-mannose, and the branch chains are located on the C6 site and the C-3 site of the 1, 2-alpha-mannose. The branches consist of galactose residues, xylose residues, mannose residues and fucose residues. In-vitro experiments prove that the polysaccharide can be used for remarkably inhibiting the expression of fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin), and can be used for remarkably inhibiting the expression of the fibrosis related proteins (Fibronectin, Collagen I and alpha-smooth muscle actin). Meanwhile, the surface plasmon resonance technology finds that the polysaccharide can be combined with PI3K protein. Therefore, the polysaccharide has a potential anti-hepatic fibrosis effect and is expected to become a candidate saccharide drug for treating hepatic fibrosis.

The invention relates to the technical field of biology, in particular to an lncRNA primer group for detecting apis cerana infected by bee glomus and application of the lncRNA primer group, and the primer group comprises the following primers: lncRNA6470-F, lncRNA6470-R, Ace-actin-F and Ace-actin-R; the nucleotide sequence of the lncRNA6470-F is as shown in SEQ ID No. 1 (sequence identifier number 1); the nucleotide sequence of the lncRNA6470-R is as shown in SEQ ID No. 2; the nucleotide sequence of the Ace-actin-F is as shown in SEQ ID No. 3; and the nucleotide sequence of the Ace-actin-R is as shown in SEQ ID No. 4. The research finds and identifies a specific lncRNA molecule, namely lncRNA6470, of which the expression is obviously changed after worker bee larvae of apis cerana are infected by bee glomus, the primer group provided by the research can be used for early diagnosis of the apis cerana chalkbrood disease, the diagnosis time is earlier than that of a traditional method, a diagnosis basis can be provided for whether bee colony larvae are infected by chalkbrood disease or not before the larvae are attacked, and the method has the advantages that the method is simple and convenient to operate, and the cost is low. A new view angle and a new target spot are provided for clarification of a molecular mechanism of Chinese bee chalkbrood disease resistance, and a theoretical foundation is laid for development of a novel bee disease prevention and control technology based on RNA interference in the future.

This invention belongs to the field of parasite detection technology, specifically relating to a lyophilized PCR kit for detecting Clonorchis sinensis in fecal samples. The lyophilized PCR kit of this invention includes a lyophilized reaction powder, a positive control, a negative control, and a reconstitution solvent. The lyophilized reaction powder is prepared by freeze-drying a reaction solution containing the following components: (a) a first primer pair and a first probe for detecting the Clonorchis sinensis COX1 gene; (b) a second primer pair and a second probe for detecting the human genomic actin (ACT) gene; (c) PCR reaction components: including hot-start Taq DNA polymerase, dNTPs, and a buffer system; and (d) a lyophilization protectant. This invention targets the Clonorchis sinensis-specific COX1 gene and uses PCR amplification technology to detect fecal samples, accurately identifying Clonorchis sinensis nucleic acid and effectively avoiding cross-reactions with other parasites and intestinal flora. The detection specificity and sensitivity are significantly improved, and the repeatability and stability are excellent.

The present application relates to the application of Paffia dura and its actin in removing cadmium in the environment; and a method for removing cadmium in the environment, comprising the following steps: exposing Paffia dura or microorganisms overexpressing actin from Paffia dura to an environment containing cadmium for incubation; removing Paffia dura from the environment. The present application finds that Paffia dura has high tolerance to cadmium stress and excellent cadmium enrichment capacity, and further finds that the main substance in Paffia dura cells combined with cadmium is actin. Therefore, Paffia dura and microorganisms overexpressing the actin can be used to treat cadmium-polluted environments to remove cadmium pollution. In addition, we also unexpectedly find that cadmium stress can up-regulate the expression of actin in Paffia dura, which is a new way to up-regulate the expression of housekeeping genes.

The application belongs to the technical field of RNA biological control, and particularly relates to application of dsRNA targeting actin coding genes. The application provides application of dsRNA targeting actin coding genes in prevention and treatment of crop anthracnose, wherein the nucleotide sequence of the dsRNA is shown as SEQ ID No. 2, the dsRNA is transcribed from a target gene segment of a Magnaporthe grisea CaACTIN gene, and the nucleotide sequence of the target gene segment of the Magnaporthe grisea CaACTIN gene is shown as SEQ ID No. 1. By loading the above dsRNA on a nano material layered double hydroxide, the pathogenicity of mango anthracnose and banana anthracnose can be obviously reduced, and the application prospect of the dsRNA in high-efficiency and targeted prevention and treatment of crop anthracnose is high.

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers thereof, which are useful for modulating or degrading proteins expressed by one or more SWI / SNF related matrix associated actin dependent chromatin regulatory factor A subfamily (SMARCA) (e.g., SMARCA2 and / or SMARCA4). I

The present invention provides immunoconjugates comprising an antigen and an F-actin-binding moiety. These immunoconjugates promote the presentation of antigens. The invention also provides vaccines that comprise or encode conjugates tint allow antigens to be presented to the immune system. Related medical uses and methods of eliciting an immune response are also provided.

The invention discloses an identification method and application of an intercellular tunnel nanotube and a transport substance thereof, and belongs to the technical field of biological identifier.The identification method of the tunnel nanotube in a fixed state comprises the following steps that a culture dish is inoculated with cells to be detected, and after fixation, permeabilization and F-actin dyeing are conducted, the cells to be detected are placed in the culture dish; performing three-dimensional imaging to obtain a three-dimensional image; based on a preset identification standard, analyzing the three-dimensional image to identify the intercellular tunnel nanotube; the method for identifying the tunnel nanotube in the living cell state and the transported substance of the tunnel nanotube in the living cell state comprises the following steps: inoculating a to-be-detected cell in the living cell state on a culture dish, carrying out living cell imaging based on a differential interference comparison system, and accurately judging the key identification key point of the tunnel nanotube, namely whether the tunnel nanotube is attached to the bottom of the culture dish or not. The method can accurately and efficiently identify and distinguish tunnel nanotubes between cells with complex forms in fixed and living cell states.

The invention provides an RNA (Ribonucleic Acid) molecular marker for judging early gonad differentiation of young river snails in China and an identification method. Dmrt1 and Foxl2 genes are important genes related to gonad differentiation of river snails. The method comprises the following steps: designing and verifying primers SEQ ID NO: 1-2 according to conserved regions of Dmrt1 and Foxl2 genes; the method comprises the following steps: collecting gonad tissue samples in a young snail stage and a sexual maturity stage, wherein n is greater than or equal to 120, extracting total RNA (Ribonucleic Acid) of a field snail tissue, carrying out reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid), detecting a double-gene expression quantity through qRT-PCR (Quantitative Reverse Transcription-Polymerase Chain Reaction), calculating a standardized expression value by taking beta-actin as an internal reference, and establishing a discrimination function D = log2 (Dmrt1 / Foxl2); 1, judging that the juvenile snails of the field snails start gonad differentiation; according to the invention, the problems of deficiency of specific molecular markers for sex differentiation of the young escargots in China and indefinite gonad differentiation time point are solved in a breakthrough manner, accurate locking of the gonad differentiation time of the young escargots is realized, the gonad differentiation time is 15-20 days earlier than morphological differentiation, and verification of more than one hundred of samples shows that the identification accuracy reaches 100%.

The invention discloses a method for evaluating senescence of dermal fibroblasts. The method comprises the following steps: measuring the assembly density of F-actin in dermal fibroblasts, and comparing with a contrast; if the assembly density is lower than that of the contrast, evaluating that the dermal fibroblasts are senescent cells or senescent cells; the control includes the assembly density of F-actin in dermal fibroblasts that are defined to be unaged. The evaluation method has the effect of screening out symptoms such as skin wrinkles, relaxation and droop caused by the change of the physical and chemical environment of the extracellular matrix.

The application provides the use of a circular non-coding RNA circKCNK2 as a biomarker for predicting bone metastasis of kidney cancer or evaluating the prognosis of kidney cancer. The application also provides a kit for predicting the progression of bone metastasis of renal cell carcinoma or evaluating the prognosis of kidney cancer, which contains primers for detecting the circular non-coding RNA circKCNK2 and detecting the internal reference beta-actin, the upstream primer sequence for detecting the circKCNK2 is shown as SEQ ID NO. 7, the downstream primer sequence for detecting the circKCNK2 is shown as SEQ ID NO. 8, the upstream primer sequence for detecting the beta-actin is shown as SEQ ID NO. 9, and the downstream primer sequence for detecting the beta-actin is shown as SEQ ID NO. 10. The application can understand the bone metastasis event and long-term prognosis of a patient by detecting the expression level of circKCNK2 in the kidney cancer tissue of the patient. It is found in the kidney cancer population that the patients with high expression of circKCNK2 are more likely to have bone metastasis-related PFS events than the patients with low expression of circKCNK2, and the survival is poor.

The invention relates to the technical field of biology, in particular to a circRNA primer group for detecting apis cerana infected by bee glomus as well as a kit and application of the circRNA primer group, and the primer group comprises the following primers: ac2651-F, ac2651-R, actin-F and actin-R; the nucleotide sequence of the ac2651-F is as shown in SEQ ID No. 1; the nucleotide sequence of the ac2651-R is as shown in SEQ ID No. 2; the nucleotide sequence of the actin-F is as shown in SEQ ID No. 3; and the nucleotide sequence of the actin-R is as shown in SEQ ID No. 4. The research finds and identifies a specific circRNA (Ribonucleic Acid) molecule ac2651 of which the expression is obviously changed after worker bee larvae of apis cerana are infected by bee glomus, the primer group provided by the research can be used for early diagnosis of the apis cerana chalkbrood disease, the diagnosis time is earlier than that of a traditional method, a diagnosis basis can be provided for whether bee colony larvae are infected by chalkbrood disease or not before the larvae are attacked, and the method has the advantages that the method is simple and convenient to operate and high in practicability. A new view angle and a new target spot are provided for clarification of a molecular mechanism of Chinese bee chalkbrood disease resistance, and a theoretical foundation is laid for development of a novel bee disease prevention and control technology based on RNA interference in the future.

The present invention relates to methods for protein production using a novel genomic integration site in the beta Actin gene locus, methods of stable cell line production, cell lines and uses thereof.

Disclosed are compounds of Formula I, or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers thereof, which are useful for modulating or degrading proteins expressed by one or more SWI / SNF related matrix associated actin dependent chromatin regulatory factor A subfamily (SMARCA) (e.g., SMARCA2 and / or SMARCA4). I

The invention provides a nucleotide sequence combination for detecting OLAH mRNA, application of the nucleotide sequence combination and a kit for detecting the expression quantity of the OLAH mRNA. The nucleotide sequence combination for detecting the OLAH mRNA comprises a detection primer pair and a detection probe, the detection primer pair comprises a first primer pair for detecting OLAH mRNA and a second primer pair for detecting actin internal reference mRNA, the base sequence of the first primer pair is as shown in SEQ ID NO.1-2, and the base sequence of the second primer pair is as shown in SEQ ID NO.4-5; the detection probe comprises a first probe for detecting OLAH mRNA and a second probe for detecting actin internal reference mRNA, the base sequence of the first probe is as shown in SEQ ID NO.3, and the base sequence of the second probe is as shown in SEQ ID NO.6; the first primer pair and the first probe are combined to obtain a first nucleotide sequence combination, and the second primer pair and the second probe are combined to obtain a second nucleotide sequence combination. The kit provided by the invention not only can detect the OLAH mRNA expression level, but also can predict the severity of respiratory tract infection, and is beneficial to quickly screening critical patients and mild patients.

Cerebral small vessel disease (SVD) is a leading cause of stroke and a major contributor to cognitive decline and dementia in the population. Evidences indicate that blood brain barrier dysfunction may play a significant role in VD pathogenesis. Recently, an inverse association of TRIM47 expression in brain and vascular tissues with extensive-SVD severity was reported in a human genome wide association study combined with summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers. Now, the inventors demonstrate TRIM47 is a key regulator of actin cytoskeleton organization through KEAP1 / NRF2 signalling pathway and might be protective from oxidative stress in brain EC. In particular, the in vitro TRIM47 knockdown decreases directed EC migration and delays EC adhesion process with loss of actin cortical reorganization and focal adhesion contacts. Furthermore, RNA sequencing and BioID results indicate that TRIM47 knockdown in brain EC, represses the expression of genes associated with cytoskeleton and NRF2 antioxidant pathway through a potential interaction with KEAP1. Accordingly, the present invention relates to the use of Nrf2 activators for the treatment of SVD.

The invention discloses a teak camel moth reference gene and application thereof. In particular to teak camel moth reference genes Actin, GAPDH, AK, RPL10, RPL13, RPL27, EF1A, SOD, Beta, S5 and 28S, and nucleotide sequences of the teak camel moth reference genes Actin, GAPDH, AK, RPL10, RPL13, RPL27, EF1A, SOD, Beta, S5 and 28S are respectively shown as SEQ ID NO: 1-SEQ ID NO: 11. The nucleotide sequence of the teak camel moth reference gene obtained by the invention can be used as a reference gene for researching teak camel moth functional genes, or gene expressions in development periods, body parts and sex in the future, or can be used as a useful method for research under treatment at different temperatures.

This invention discloses the internal reference gene of the citrus psyllid, its primers, and applications, belonging to the field of genetic engineering technology. Through screening, this invention identifies Actin, the most stable and superior internal reference gene for the citrus psyllid. This invention finds that Actin exhibits the lowest expression stability in different sexes, different tissues and organs, different developmental stages, and different disease states of the citrus psyllid, making it the most stable internal reference gene for related gene expression studies in the citrus psyllid. This lays the foundation for research on the biological characteristics and disease transmission mechanisms of the citrus psyllid and also provides a theoretical reference for the study of internal reference genes in other homoptera insects.

The invention provides application of raltegravir in preparation of a medicine for preventing and / or treating vascular remodeling diseases. A series of in-vitro cell experiments find that the Rategravir can influence activation of a Hippo / YAP pathway by inhibiting polymerization from gamma-actin to F-actin, further inhibit abnormal proliferation and migration ability of pulmonary artery smooth muscle cells (PASMCs) and inhibit conversion of the PASMCs from a contraction type to a synthetic type, so that pulmonary vascular remodeling is improved, and the pulmonary vascular remodeling effect is improved. The pulmonary vascular remodeling is expected to be fundamentally inhibited or reversed, and the prevention and treatment effects on pulmonary arterial hypertension are improved. Furthermore, the treatment effect of the Rattegravir in vivo is verified through a pulmonary arterial hypertension animal model. In a word, the invention discovers that the Rattegravir can achieve the purpose of preventing and treating pulmonary arterial hypertension from the pathogenesis level, and has a good application prospect and a higher clinical application value.